Skip to main content

Attovia Therapeutics, Inc.

corporate_fare Company Profile

Attovia Therapeutics, Inc.

ATTO·NASDAQ·Life Sciences

Frazier Life Sciences XI, a 10% owner of Attovia Therapeutics, purchased $10 million of common stock at $17.00 per share and converted preferred shares into 5.49 million common shares upon the IPO closing.

Attovia Therapeutics, Inc. (NASDAQ:ATTO) is a publicly traded company in the Life Sciences sector. Wiseek monitors ATTO SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • Frazier Life Sciences XI Buys $10M of ATTO Stock at $17, Converts Preferred Shares
$20.56 +0.18% today
52-week range · as of 2026-08-06 $19.63 – $22.79
Market cap
$785.22M
Volume
413.2K (0.2× avg)
3-mo avg 2.7M
Live data · 2026-08-07 00:45 UTC · Market overnight

show_chartPrice Chart

Loading chart...

feed ATTO - Latest Insights

ATTO
Aug 06, 2026, 5:35 PM EDT
Filing Type: 4
Importance Score:
8
Frazier Life Sciences XI Buys $10M of ATTO Stock at $17, Converts Preferred Shares
Price at Filing: $20.56
Real-time Price: $20.56 info
Change: $0 (0%) info
Market Cap: $785.221M info
Sentiment: Positive
View Wiseek Article